Beta-adrenergic receptor blocking drugs in hypertension.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000526:Alprenolol / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001249:Asthma / Q000139:chemically induced; D004232:Diuretics / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005730:Ganglionic Blockers / Q000627:therapeutic use; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007989:Libido / Q000187:drug effects; D010096:Oxprenolol / Q000627:therapeutic use; D010869:Pindolol / Q000627:therapeutic use; D011217:Practolol / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D011600:Psychopharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D013015:Sotalol / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000928:Antidepressive Agents; D000959:Antihypertensive Agents; D004232:Diuretics; D005730:Ganglionic Blockers; D014665:Vasodilator Agents; D010096:Oxprenolol; D000526:Alprenolol; D011433:Propranolol; D013015:Sotalol; D010869:Pindolol; D011217:Practolol